Producing DNA templates of short lengths is not especially challenging. But at longer lengths accuracy becomes a challenge and a bottleneck. Even as applications like mRNA therapeutics, gene and cell therapies, and genome engineering accelerate, the underlying chemistry and workflows used to make DNA still introduce errors and contaminants that can derail entire programs. This article explores why sequence accuracy is so hard to achieve, how errors compound in synthetic DNA, and why cell‑free, enzymatic synthesis is emerging as a scientifically robust way to change the equation.
Sequence accuracy and construct length are critical
How single‑base errors can derail an entire program. Current gene synthesis processes, which rely on phosphoramidite‑based oligonucleotide synthesis and subsequent assembly, typically exhibit error rates on the order of 1–10 errors per kilobase (102–103).1 At first glance that might seem acceptable, but every step, including oligo synthesis, assembly, cloning, and amplification, adds new opportunities for mistakes, and small per‑step error rates accumulate across hundreds or thousands of bases. As constructs become longer and more complex, the probability that at least one base is wrong increases sharply.
A single incorrect base can change a codon, alter an amino acid, or introduce a premature stop, with knock‑on effects on protein folding, activity, or immunogenicity. For regulatory elements, such as promoters or polyA signals, a single mismatch can compromise expression levels or RNA stability. For CRISPR homology‑directed repair templates and CAR‑T vectors, base‑level errors can mis‑align homology arms or payloads, reducing editing efficiency or creating off‑target integrations. Similarly, in IVT templates for mRNA therapeutics, an error in coding sequence may yield heterogeneous transcripts, complicating downstream characterization.
Challenges in producing accurate, clean synthetic DNA
Reason 1: Accuracy limits in phosphoramidite‑based chemical synthesis
Most synthetic DNA today still starts with phosphoramidite chemistry, where each nucleotide is added through a cycle of detritylation, coupling, capping, and oxidation on a solid support. Per‑step coupling efficiencies can exceed 99%, but when hundreds of cycles are chained together, even small inefficiencies accumulate into a meaningful fraction of truncated or mis‑modified products. Side reactions during this cycle are a primary source of errors
Depurination is one of the best studied side reactions: under acid detritylation conditions, purine bases can be lost, creating abasic sites and ultimately strand cleavage. Incomplete coupling leads to deletion mutations if capping is not perfectly selective, because unreacted sites can participate in later cycles. Additional by‑products arise from oxidation and base modifications, which alter hydrogen‑bonding patterns and create mispairing during subsequent assembly and PCR. Even after chromatographic purification, imperfect oligonucleotides are assembled into larger constructs, and polymerase‑mediated extension can convert latent chemical lesions into permanent sequence changes. The result is that each synthetic and enzymatic step carries its own error profile, and errors compound as constructs grow longer and more complex.
If your workflows rely heavily on plasmid‑based templates, one way to start addressing these accuracy limitations is to begin with cleaner, high‑accuracy cell‑free DNA rather than traditional plasmids—something you can evaluate directly by making cell‑free DNA at your lab bench with MiroMine and benchmarking it against existing constructs.
Reason 2: Purity and contaminants in plasmid‑based workflows
Accuracy isn’t the only concern: purity and contamination are recurring challenges in plasmid‑based DNA production. In many pipelines, synthetic sequences are cloned into plasmids, propagated in Escherichia coli, and purified using standard plasmid prep and chromatography. This approach is mature and scalable, but it inherently introduces bacterial components that have to be removed—or at least controlled—to meet research and therapeutic standards.
Endotoxin, the lipopolysaccharide component of Gram‑negative bacterial outer membranes, can co‑purify with plasmid DNA and is a major safety and regulatory concern, especially for gene and cell therapy, viral vectors, and mRNA production. Residual host proteins, genomic DNA, and antibiotic resistance markers may also be present, even after multiple purification steps, complicating downstream characterization and risk assessments. Additionally, unwanted plasmid backbone elements—origins of replication, selection markers, and other non‑payload sequences—can carry over into IVT templates or donor constructs and affect expression systems or regulatory perceptions.
These contaminants are not trivial to remove completely; achieving low endotoxin levels often requires extensive polishing, and confirming the absence of backbone sequences demands thorough sequence verification. All of this adds cost, time, and complexity on top of the intrinsic sequence accuracy challenges. Taken together, the combination of chemical‑synthesis‑related errors and plasmid‑associated contaminants means that long, therapeutic‑grade DNA often faces both fidelity and purity hurdles
How cell‑free, enzymatic DNA synthesis changes the equation
Mechanistic differences: enzymatic vs chemical plus cloning
Cell‑free, enzymatic DNA synthesis takes a different route: instead of relying on bacterial cloning for amplification, these platforms assemble and amplify DNA directly in vitro using enzymes such as polymerases and ligases, often starting from shorter, sequence‑verified building blocks. This approach sidesteps many of the harsh chemical conditions and biological steps that introduce errors and contaminants in conventional pipelines
By avoiding repeated acid detritylation cycles, cell‑free workflows reduce depurination and other base‑damaging reactions that plague long phosphoramidite products. Template‑guided enzymatic assembly can be designed to favor correct pairing, and when combined with modern error‑correction strategies, such as mismatch‑binding proteins and endonuclease treatments, it offers a route to lower overall error burdens. Recent data from enzymatic dsDNA providers and application notes show high fractions of sequence‑correct molecules across a wide range of lengths, with reported error rates significantly below traditional gene synthesis baselines.
Impact on purity and regulatory friendliness
Because cell‑free platforms do not propagate DNA in bacteria, they eliminate endotoxin and host‑derived contaminants at the source, and they avoid plasmid backbones altogether. The resulting dsDNA is typically backbone‑free, with sequences limited to the desired payload and any intentionally designed elements, which simplifies QC expectations and regulatory review. For mRNA IVT templates, this reduces the risk of plasmid backbone carryover and improves template homogeneity. For gene and cell therapy donors, cleaner DNA reduces the burden of demonstrating absence of antibiotic resistance markers or extraneous elements.
Several studies and case examples have now demonstrated that cell‑free enzymatic DNA can support complex workflows—from one‑shot cell‑free protein engineering to high‑throughput screening pipelines—while maintaining high sequence accuracy and length purity. As these methods continue to mature, they offer a scientifically grounded path toward DNA that is both more accurate and cleaner than traditional plasmid‑derived constructs. If you are interested in testing this approach, you can make cell‑free DNA at your lab bench with MiroMine and directly compare sequence fidelity, purity, and performance to your existing templates.
Conclusion
Accurate, clean synthetic DNA is foundational for today’s most advanced therapies, yet traditional phosphoramidite and plasmid‑based pipelines still face inherent limitations that drive cumulative errors and contamination. Cell‑free, enzymatic synthesis offers a scientifically grounded alternative that targets both fidelity and purity, and as these methods become more accessible at the lab bench, they are poised to become a new standard for building the long, complex DNA molecules that modern biotech demands.
